Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight

DelveInsight projects steady expansion of the sarcoidosis treatment market across the US, EU4, UK and Japan through 2036, driven by higher diagnosis rates and demand for steroid-sparing therapies. The pipeline includes efzofitimod, brepocitinib, OATD-01 and XTMAB-16; efzofitimod has orphan-drug designations in the US, Europe and Japan and a proposed global Phase 3 pulmonary-sarcoidosis program. Priovant reported positive Phase 2 results for brepocitinib in cutaneous sarcoidosis and plans to begin Phase 3 in 2026, while XTMAB-16 reported preliminary safety and corticosteroid-reduction signals.

Analysis

This is not a sector-wide read-through; the only liquid, directly exposed equity is ATYR. The investable question is whether efzofitimod can convert steroid reduction into a regulator- and payer-acceptable clinical benefit in pulmonary sarcoidosis. Orphan/Fast Track status improves process visibility but does not de-risk efficacy, and the lack of disclosed market-sizing, pricing, treated-population, and pivotal endpoint details makes the promotional long-term market forecast insufficient for model revisions today.

Near term (days to 3 months), ATYR can attract retail/biotech-flow interest, but sustainable upside requires FDA alignment on a registrational path and clarity on the post-Phase 3 evidence package. Over 6-18 months, successful development would have greater value through expansion across immune-mediated ILD than through sarcoidosis alone; conversely, a pulmonary-sarcoidosis failure would impair both platform validation and partnership optionality. Xentria, Molecure and Priovant are largely private/non-investable, limiting clean public pair opportunities.

Contrarian view: the crowded pipeline may cap peak pricing and penetration rather than validate a large winner-take-most market. Payers will likely require demonstrated reduction in cumulative steroid toxicity, exacerbations, hospitalizations, or durable lung-function preservation—not merely biomarker or short-duration patient-reported outcomes—before reimbursing a premium biologic ahead of low-cost generic immunosuppressants. Mallinckrodt's Acthar franchise is more exposed to eventual share erosion, but the company is not supplied as a directly actionable listed ticker here.

Key Decisions for Investors

• Maintain ATYR on catalyst watch rather than chase the press-release move. Initiate only after FDA-confirmed registrational design and disclosed endpoint/power assumptions; size as a binary biotech position with a 6-12 month horizon, targeting at least 2.5:1 upside/downside based on probability-adjusted approval economics.
• For an existing ATYR position, trim into unexplained near-term strength and retain a smaller core through regulatory updates. Thesis is falsified by an FDA request for another efficacy study, a change to a hard clinical endpoint that materially lengthens timelines, or guidance implying cash runway below the next decisive readout.
• Do not extrapolate to INSM, GOSS, AVLN, LQDA, UTHR, AZN, BMY, GSK, NVS, or PFE: shared ILD/immune-inflammation exposure is too indirect for a sarcoidosis-specific revenue or valuation read-through.
• Set an alert for ATYR disclosures on baseline steroid dose, forced vital capacity trajectory, responder durability, safety versus broad immunosuppression, and financing plans. These variables—not awareness-driven epidemiology forecasts—determine adoption, launch price, dilution risk, and enterprise value.